Association between inflammatory airway disease of horses and exposure to respiratory viruses: a case control study

Table 1 Descriptive statistics for the study population

Group	Number	Age	Clinical signs (total number, percent)			BAL		Pulmonary function tests
Group	Number	Age	Cough	Exercise intolerance/poor performance	Nasal discharge	PMN	Mast	Histamine (PC75R_RS or PC50DF)	Albuterol (>25 % decrease)
Control	14	14.5 ± 1.99 (5–26)	0 (0)	4 (29 %)	0	2.7 ± 1.6 (0–5)	0.5 ± 1.6 (0.0–1.8)	13.48 ± 1.17 (6.7–24.0)	None
IAD	24	16.2 ± 0.9 (9–25)	18 (75 %)	20 (83 %)	4 (16.7 %)	22.5 ± 4.4 (0.0–85.0)	3.29 ± 0.7 (0.0–16.0)	5.25 ± 0.90 (0.5–16.9)	3

All horses had history, clinical examination, bronchoalveolar lavage, and baseline pulmonary function testing performed. The majority of horses had HBP performed; 3 horses with R_RS > 1.5 cmH₂O/l/s had albuterol challenge performed with at least 25 % decrease in RRS. Cough, exercise intolerance/poor performance, and nasal discharge reflect the owner complaint. PMN and mast refer to the neutrophil and mast cell percentages found on cytology of BALF. Histamine refers to the results of a histamine bronchoprovocation test using either FOM or Open Pleth. A lower number indicates greater reactivity of the airways. Albuterol indicates that the horse was given albuterol after baseline pulmonary function testing with at least 25 % decrease in respiratory resistance

ISSN: 2049-6958